Introduction: The WHO estimates that 180 million people are chronically infected with hepatitis C virus (HCV) throughout the world. Despite the emergence of new therapies, the combination of pegylated interferon and ribavirin remains the accepted standard of care in lowincome countries, including Mexico. Two types of peginterferon are available (peginterferon alfa-2a and peginterferon alfa-2b), and both are recommended for the treatment of HCV, although there is controversy over which treatment option is most effective. Methodology: This was a retrospective cohort study at a infectious disease center in Mexico City. Patients were included if they had received peginterferon alfa-2a or peginterferon alfa-2b plus ribavirin. Age, sex, body mass index, AST platelet ratio index, HCV RNA viral load, levels of alanine aminotransferase, aspartate aminotransferase, bilirubin, albumin, and hemoglobin, and platelet and leukocyte counts of the subjects were assessed before treatment and at weeks 4, 12, 24, 48, and 6 months post treatment. Results: Eighty-seven patients met the inclusion criteria. A sustained virological response (SVR) occurred in 33 (38%) of them, 11 (33%) given peginterferon alfa-2a and 22 (67%) given peginterferon alfa-2b (p = 0.17). Seventeen patients (20%) relapsed, 7 (41%) of those given peginterferon alfa-2a and 10 (59%) of those given peginterferon alfa-2b (p = 0.76); 27 (31%) patients were non-responders (p = 0.09). The rates of anemia, thrombocytopenia, and leukopenia were similar in both groups. Conclusions: Similar SVR rates and frequencies of adverse events were observed. Either type of interferon can be used to treat HCV infection in the Mexican population
Introduction
The World Health Organization estimates that 180 million people are chronically infected with hepatitis C virus (HCV) throughout the world [1] . Up to 85% of HCV-infected individuals go on to develop chronic hepatitis C (CHC), which carries risks of progression to cirrhosis, end-stage liver disease, and hepatocellular carcinoma [2] . During the natural course of CHC, the spontaneous eradication of HCV infection occurs extremely rarely [3] . Despite the emergence of new therapies, the combination of pegylated interferon alfa (peginterferon) and ribavirin remains the accepted standard of care (SOC) in Mexico. The primary goal of HCV therapy is to cure the infection by eliminating detectable circulating HCV after the cessation of treatment [4] . Two types of peginterferon are available -peginterferon alfa-2a and peginterferon alfa-2b -and both are recommended for the treatment of HCV, although there is controversy over which treatment option is the most effective [5, 6] . Well-known factors that affect the response to treatment include baseline characteristics such as the HCV genotype, HCV RNA viral load, age, and the degree of fibrosis [7] . In patients infected with HCV genotype 1, the sustained virological response (SVR) rates after the accepted SOC are around 40% worldwide [8] .
The prevalence of HCV infection in Mexico is 1.4% (700,000 individuals), and the main genotype is 1 [9] . There is evidence of a more aggressive CHC course in Latin American patients who have higher serum levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), and total bilirubin, lower albumin levels and higher portal inflammation scores in liver biopsies. The available information suggests that there is more rapid progression of liver disease because of the low efficacy of current therapies [10] .
A few studies have compared the effectiveness and safety of peginterferon alfa-2a and alfa-2b, but all have used different statistical designs and the results are inconclusive [2, 5, 6, 8] . However, clinical trials provide a high level of medical and supportive care, which tends to maximize patient compliance, and the inclusion and exclusion criteria may not reflect the clinical picture in a real-life setting [11] . Thus, the main objective of this study was to conduct a "reallife" comparison of peginterferon alfa-2a versus alfa2b plus ribavirin in a Mexican population with HCV genotype 1.
Methodology

Study design
A retrospective cohort study was conducted at a single infectious disease center in Mexico City, approved by the local ethical committee with reference number R-2013-35021-6. Patients who were older than 16 years with HCV genotype 1 infection and a detectable HCV RNA viral load were enrolled. Patients were included if they had received treatment with peginterferon alfa-2a or peginterferon alfa-2b plus ribavirin between December 2008 and December 2012 at the Hospital de Infectologia La Raza National Medical Center in Mexico City. Complete records were collected, including hematological and biochemical data. Patients who were coinfected with human immunodeficiency virus (HIV) or hepatitis B virus (HBV) were excluded.
Patients and measurements
Patients' age, sex, body mass index, hepatic fibrosis AST-platelet ratio index (APRI) score, HCV RNA viral load, levels of ALT, AST, bilirubin, albumin, and hemoglobin, and platelet and leukocyte counts were assessed. These were measured before the first peginterferon dose and at weeks 4, 12, 24, 48, and 72 (in patients with a delayed virological response), and at 6 months post treatment. The response rates were classified as a rapid virological response (RVR), early virological response (EVR), and SVR. Any adverse hematological events at weeks 4, 12, and 24, and at the end of the treatment were recorded. The end-of-treatment response and SVR were defined as a negative quantitative HCV RNA level at the end of treatment and after 24 weeks in an untreated followup, respectively. An EVR was defined as a quantitative HCV RNA-negative (complete EVR) or a reduction from the baseline HCV RNA level of < 2 log 10 IU/mL at week 12 (partial EVR). All patients with detectable HCV RNA at week 24 stopped treatment and were classified as nonresponders. Virological relapse was defined as reversion to HCV RNA-positive status in a patient who had an undetectable HCV RNA level (< 43 IU/mL) at the end of the treatment.
Adverse events and dose reductions
Anemia was defined as a hemoglobin level of < 12 g/dL for women and < 13 g/dL for men. Thrombocytopenia was defined as a platelet count of < 50,000 platelets/dL. Leukopenia was defined as a leukocyte count of < 4,000 cells/dL, and neutropenia as a neutrophil count of < 1,000 cells/dL. The dose of peginterferon alfa-2a was reduced from 180 to 135 g/week and then to 90 g/week. The dose of peginterferon alfa-2b was reduced from 1.5 to 1.0 g/kg/week and then to 0.5 g/kg/week if the absolute neutrophil count decreased to < 750/mm 3 or if the platelet count decreased to < 50,000/mm 3 . Treatment was stopped if the neutrophil or platelet count decreased to < 500/mm 3 or < 25,000/mm 3 , respectively. The dose of ribavirin was reduced by 200 mg/week if the hemoglobin level decreased to < 10 g/dL, and ribavirin was stopped if the hemoglobin level decreased to < 8.5 g/dL [4] .
Statistical analysis
The statistical analysis was based on the median and interquartile range (IQR, 25th to 75th percentile range). A  2 test was used to compare categorical variables. Multivariable logistic stepwise regression analysis was used to explore the independent effects of the treatment and the baseline factors (age, body weight, body mass index, sex, presence of cirrhosis, ALT level, HCV RNA level, and HCV genotype) on the likelihood of achieving an SVR. All tests were two sided, and p < 0.05 was considered to be significant. The tests were conducted using SPSS software version 20.
Results
A total of 199 records of patients with HCV infection who received treatment were reviewed. Of these, 87 patients met the inclusion criteria; the others were treatment-experienced patients. The median age was 50 years (IQR, 42-59), and 52 (60%) patients were women. Forty-six (53%) patients had subtype 1b. The other baseline data are included in Table 1 . Thirty-seven (43%) patients received treatment with peginterferon alfa-2a, and 50 (57%) patients received peginterferon alfa-2b (Table 1) .
Virological response
Thirty-seven patients received treatment for 48 weeks, 11 patients for 72 weeks because of a delayed viral response, and 18 patients stopped treatment in week 12: two because of adverse events and 16 because of a null response. Ten patients were partial responders. An SVR at week 24 (SVR24) occurred in 33 (37%) of these patients: 11 (33%) given peginterferon alfa-2a and 22 (67%) given peginterferon alfa-2b (p = 0.17). An RVR occurred in 17 patients, and 56 (64%) patients achieved an EVR (Figure 1 ). Of the patients who lacked an SVR24 (n = 54), 17 (31%) relapsed: 7 (41%) given peginterferon alfa-2a and 10 (59%) given peginterferon alfa-2b (p = 0.76).
Twenty-seven (31%) patients were nonresponders (p = 0.09, peginterferon alfa-2a vs alfa2b) ( Table 2) . Five patients received shortened treatment by 24 weeks (baseline viral load < 800,000 IU/mL, low-level fibrosis indicated by the APRI score, and an RVR); all of these patients had an SVR24.
The predictive factors associated with an SVR were evaluated. To identify the independent factors, multivariable logistic regression analysis was used. Only age < 40 years, RVR, and EVR were significantly associated with an SVR (Table 3) . Adverse events Treatment was suspended for six patients because of adverse events: four because of rash, one because of anemia, and one because of hepatic encephalopathy. The major adverse hematological effects are shown in Table 4 .
Discussion
Mexico is a developing country, and the economic resources devoted to health care are limited. Around 90% of patients with VHC are treated in government hospitals and do not have access to direct antiviral agents. In Mexico, treatment with pegylated interferon alfa plus ribavirin remains the only option for almost all of the population.
In this study, we confirmed the same response rate to either of the pegylated interferons used to treat HCV genotype 1 infections in this Mexican population. Similar to Rodriguez-Torres et al., who in 2009 reported an SVR rate of 34% in a Latino population compared with an SVR of 49% in a nonLatino population, we found an SVR rate of 37.9% [12] . The IDEAL study by McHutchison et al. reported similar SVR rates of 40.9% (95% confidence interval [CI], 37.9-43.9) with peginterferon alfa-2a and 39.8% (95% CI, 36.8-42.8) with peginterferon alfa-2b (p = 0.57) [8] . In 2011, Zurwiesch et al. studied a German cohort of 486 patients and reported no significant difference in the SVR rates with peginterferon alfa-2a (53.4%) and alfa-2b (53.7%) [11] . However, some authors have reported better responses with peginterferon alfa-2a. In 2010, Ascione et al. reported a prospective single-center, open-label randomized trial (n = 320), which showed that 54.8% of patients treated with peginterferon alfa-2a had an SVR compared with 39.8% of patients treated with peginterferon alfa-2b (95% CI, 0.72-28.5; p = 0.040) [5] . Similar results were reported by Rumi et al. in a single-center, open-label randomized trial, which found response rates of 48% in patients who received peginterferon alfa-2a (n = 212) and 32% in patients who received peginterferon alfa-2b (n = 219) (p = 0.04) [13] . Berak et al. found no differences in SVR or relapse rates between the two interferons in the treatment for HCV in a Spanish cohort. They suggested that the advantage of interferon alfa 2b is that it makes continuation of therapy for > 12 weeks unnecessary for patients who are unlikely to respond [14] .
We evaluated factors that may be related to the treatment response, such as RVR, EVR, age, sex, hepatic fibrosis (APRI score), RNA HCV viral load, obesity, and AST level. The stepwise logistic regression model identified only three factors as being independently related to an SVR in the two groups: age < 40 years, RVR, and EVR.
McHutchison et al. found that age < 40 years, basal HCV RNA level < 400,000 IU/mL, fibrosis, and RVR or EVR were predictors of an SVR. Our univariate analysis showed that age < 40 years, HCV RNA viral load < 400,000 IU/mL, RVR, and EVR were predictors of an SVR, but the only factors that remained significant in the multivariate analysis were age < 40 years, RVR, and EVR. There was no difference in the rate of adverse hematological events between the two treatment groups.
The rate of relapses was 19% in the present study and did not differ between the two groups. By contrast, Ascione et al. reported a significant difference in relapse rates: 20.4% with peginterferon alfa-2a and 9.7% with peginterferon alfa-2b (95% CI, 0.38-21.2; p = 0.040) [5] . In the IDEAL study, McHutchison et al. reported relapse rates of 31.5% for peginterferon alfa-2a and 23.5% for alfa-2b, although these did not differ significantly [8] . In 2009, Rodríguez Torres et al. reported relapse rates of 36% in Latin-American patients compared with 26% in a non-Latino population [12] . They also showed that in the Latin-American population, greater weight and obesity were significantly related to the SVR; 65% of the treated patients in their study had a body mass index of > 27 kg/m 2 . In our study, 52% of patients were overweight. We had expected that being overweight would be related to the SVR rates, but our sample size was small to support any difference related to body weight. In addition, we could not assess insulin resistance, which is also associated with a worse prognosis in Latin American patients.
The present study was a real-life comparison of the two accepted pegylated interferons used to treat infections with HCV genotype 1 and is the first of its kind in a Mexican population. All patients were ambulatory and learned how to administer the peginterferon themselves or were aided by a close relative, so our study gave an insight into how the drug works in a real-life population. Most of our population does not have access to the new antiviral drugs and therefore must continue using pegylated interferon and ribavirin. Our study shows that either of the pegylated interferons is a good option for this population. The main weaknesses of our study are that it was a cohort design and that we worked with medical records, and thus we lacked data such as information about psychiatric events. We could not assess the ribavirin dose adjustment in all patients and could not evaluate the effect of this adjustment on the SVR. Some studies have suggested that a lower dose of ribavirin may affect the SVR in patients treated with peginterferon alfa-2a. The practice in our unit is to try to maintain a ribavirin dosage at > 600 mg every 24 hours. Our center is a tertiary referral hospital, and we included only HCV treatment-naïve infected patients, which is why we had a small sample size. This may have limited the ability of our multivariate analysis to identify more than three predictors of an SVR.
Conclusions
Our results suggest that either of the pegylated interferons can be used to treat HCV infection in the Mexican population. Both interferons should be expected to have similar virological response rates and the same frequencies of adverse events.
